Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-04

Reporting Person: SHAH MAHENDRA (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14285	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$0.00		Common Stock (944056)		Indirect
Series B Preferred Stock	$0.00		Common Stock (472296)		Indirect
Warrant (Right to Buy)	$0.07	2028-07-26	Common Stock (17711)		Indirect

Footnotes

F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F2: The Series A-1 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series A-1 Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer (the "IPO").

F3: The Series B Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series B Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the IPO.

F4: The shares subject to this warrant are fully vested.

F5: This warrant will automatically be net exercised upon closing of the IPO if it is not exercised on or before such date.